u/nadia_bakker

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

a mechanism you can state is not a mechanism you have demonstrated

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.

Do you have the publication or a summary of it?

Which receptor family are you attributing that effect to?

How many separate lots has anyone here tested?

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

glucagon agonism and energy expenditure is the mechanistic thread

Adding the standing caveat — unapproved compound, research material is not for human use.

nausea profile in the combination trials is the thing to read carefully

amylin and GLP-1 are not redundant pathways

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

Is there any human data on that mechanism yet?

phase 2 in liver disease is a different evidence question from weight

independent purity data on this compound is thin

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

do not chase somebody else’s titration schedule, they are not you

My stall was eleven weeks. Eleven. Then it moved again without me changing anything at all.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.

The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.

Same. I sat at 0.5mg for three months because it was working and there was nothing to fix.

Is that a weight number from a different programme?

Yes. Week 5 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

the titration in the trials was slow and deliberate

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

This is the split the whole board depends on. Authorisation is European; payment is national.

Kept a log from week one and the single most useful column turned out to be waist, not weight.

That is an escalation schedule for an unapproved compound and this board does not host those.

Cosigning. The appetite change and the scale change ran about three weeks apart for me too.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

pharmacy margins are regulated differently in each country

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

dose day drift of a day either way is fine, the curve barely notices